BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38174993)

  • 21. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
    Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z; Sarmiento JM; Ahmed R; Maithel SK; El-Rayes BF; Lesinski GB
    Mol Cancer Ther; 2021 Jan; 20(1):150-160. PubMed ID: 33037138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
    McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
    Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
    Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
    Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
    Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
    Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
    Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
    [No Abstract]   [Full Text] [Related]  

  • 28. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chloroquine Potentiates the Anticancer Effect of Pterostilbene on Pancreatic Cancer by Inhibiting Autophagy and Downregulating the RAGE/STAT3 Pathway.
    Chen RJ; Lyu YJ; Chen YY; Lee YC; Pan MH; Ho YS; Wang YJ
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
    Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
    Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
    Toste PA; Nguyen AH; Kadera BE; Duong M; Wu N; Gawlas I; Tran LM; Bikhchandani M; Li L; Patel SG; Dawson DW; Donahue TR
    Mol Cancer Res; 2016 May; 14(5):437-47. PubMed ID: 26979711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro.
    Miyazaki Y; Oda T; Mori N; Kida YS
    FEBS Open Bio; 2020 Nov; 10(11):2268-2281. PubMed ID: 32931156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration.
    Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C
    Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression.
    Iwamoto C; Ohuchida K; Shinkawa T; Okuda S; Otsubo Y; Okumura T; Sagara A; Koikawa K; Ando Y; Shindo K; Ikenaga N; Nakata K; Moriyama T; Miyasaka Y; Ohtsuka T; Eto M; Akashi K; Nakamura M
    Cancer Lett; 2021 Aug; 512():15-27. PubMed ID: 33961925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer.
    Steele NG; Biffi G; Kemp SB; Zhang Y; Drouillard D; Syu L; Hao Y; Oni TE; Brosnan E; Elyada E; Doshi A; Hansma C; Espinoza C; Abbas A; The S; Irizarry-Negron V; Halbrook CJ; Franks NE; Hoffman MT; Brown K; Carpenter ES; Nwosu ZC; Johnson C; Lima F; Anderson MA; Park Y; Crawford HC; Lyssiotis CA; Frankel TL; Rao A; Bednar F; Dlugosz AA; Preall JB; Tuveson DA; Allen BL; Pasca di Magliano M
    Clin Cancer Res; 2021 Apr; 27(7):2023-2037. PubMed ID: 33495315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.